Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.